D-0619-2018 Class III Terminated

Recalled by InvaGen Pharmaceuticals, Inc. — Hauppauge, NY

FDA drug recall D-0619-2018 was initiated by InvaGen Pharmaceuticals, Inc. on Mar 15, 2018 and is designated Class III. Reason for recall: Failed Dissolution Specifications; during stability testing The recall status is terminated (terminated Sep 15, 2021).

Recall Details

Product Type
Drugs
Report Date
Apr 11, 2018
Initiation Date
Mar 15, 2018
Termination Date
Sep 15, 2021
Voluntary/Mandated
Voluntary: Firm initiated

Product Description

buPROPion HCl Extended-Release Tablets, USP (SR), 150 mg ,a) 60 count (NDC 69097-878-03) and b) 100 count (NDC 69097-878-07) bottles, Rx Only, Manufactured for: Cipla USA Inc. 1560 Sawgrass Corporate Parkway Suite 130 Sunrise, FL 33323, Manufactured by: InvaGen Pharmaceuticals, Inc. (a subsidiary of Cipla Ltd.) Hauppauge, NY 11788

Reason for Recall

Failed Dissolution Specifications; during stability testing

Distribution Pattern

Nationwide

Code Information

a) Lot I1606609 and Lot I1606610 Exp. Date 05/2018; Lot I1610639 Exp. Date 09/2018 b) Lot #I1606610 Exp Date 05/2018; Lot I1607847 and Lot I1607845 Exp Date 06/2018; Lot I1610639 Exp Date 09/2018

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0619-2018
openFDA file date
Nov 3, 2026
Loaded by RegDataLab
Nov 4, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0619-2018. Report a data issue: hello@regdatalab.com.